Navigation Links
Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR

of programmed cell death, was observed and PX-866 also inhibited invasive and angiogenic capabilities of cultured glioma cells. In animals, PX-866 inhibited subcutaneous tumor growth by 84 percent after 4 weeks of oral dosing and increased median survival of animals with intracranial tumors. The authors conclude that PX-866 is a highly promising PI3 kinase inhibitor in glioblastomas and other tumors with aberrant PTEN/PI3K expression, which include advanced ovarian, breast and prostate cancers, as well as lung and head and neck cancers.

Dr. Koul and colleagues at MDACC conducted the studies in collaboration with Dr. Lynn Kirkpatrick, Biomira's Chief Scientific Officer, under a grant from the U.S. National Institutes of Health.

About PX-866

PX-866 is an inhibitor of the phosphatidylinositol-3-kinase (PI3 kinase)/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. PI3 kinase is overexpressed in a number of human cancers, especially ovarian, colon, head and neck, urinary tract, and cervical cancers, where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). In preclinical studies, PX-866 has been shown to induce prolonged inhibition of tumor PI3 kinase signaling following both oral and intravenous administration. The compound also has been shown to have good in vivo anti-tumor activity in tumor models of human ovarian and lung cancer, as well as intracranial glioblastoma.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the pre-
'"/>




Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:8/29/2014)... 29, 2014   Mast Therapeutics, Inc. ... today that Santosh Vetticaden, Chief Medical Officer and ... for personal reasons, in mid-September.  Edwin L. ... Aires Pharmaceuticals, which Mast acquired earlier this year, ... Company,s interim Chief Medical Officer.  Dr. Parsley previously ...
(Date:8/29/2014)... 2014  BC Technical, the nation,s leading non-OEM provider ... a leader in sales, service and installation of GE ... Technical to continue to expand their resources and inventory ... modalities. "We are committed to driving ... , president and CEO of BC Technical. "We set ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4BC Technical Acquires Polaris Medical Imaging 2US CNS Disorders Drug Pipeline Insight 2014 2
... Phase I data from XL880, Phase II data from ... SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ --,Exelixis, Inc. ... investigational compounds XL880 and XL999 will be,presented at the ... is being held June 1 to 5 in Chicago,Illinois. ...
... many as,first-line in secondary stroke prevention , ... presented today at the,16th European Stroke Conference in ... dipyridamole plus ASA,is marketed as Aggrenox® or Asasantin® ... vascular events in patients who had,a TIA or ...
Cached Medicine Technology:Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference 2New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 2New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 3New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 4
(Date:8/31/2014)... Mesa, Arizona (PRWEB) August 31, 2014 For ... ragweed is likely the culprit. Ragweed is the most common ... percent of Americans. , The most common symptoms of ragweed ... and throat, and sneezing. Ragweed allergy can also lead to ... ragweed allergies should consult an allergist about allergy immunotherapy - ...
(Date:8/31/2014)... (PRWEB) September 01, 2014 In order to ... Co.,LTD has announced its latest designs and launched a big ... quality cars. , All the company’s new cars are ... car solutions for the global customers. As a matter of ... high end items. Those who are in need of cheap ...
(Date:8/31/2014)... 31, 2014 LabDoor.com tests the purity ... supplements. According to their website, “We buy products in ... retail stores and online sites. No manufacturer-supplied samples are ... “Stay Healthy with LabDoor,” a recent study was performed ... in the United States for Vitamin D3 content, ...
(Date:8/31/2014)... In the wake of growing consumer concerns ... to require mandatory labeling of GMOs on food and ... that affect their own health and the health of ... measures to eliminate GMOs from dietary supplements, NutriGold has ... initiative with the objective of advancing the non-GMO ...
(Date:8/31/2014)... St. Louis (PRWEB) August 31, 2014 Twin ... identical twins Aiden and Blake Colp before they were born, but ... Care Institute gave them the chance at life. , Now, ... TTTS and the life-saving fetal surgery option available in St. Louis ... TTTS awareness nights at Market Pub House (6655 Delmar Blvd, ...
Breaking Medicine News(10 mins):Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 2Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 4Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 2Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 3
... D,ALENE, Idaho, Feb. 28 NightHawk,Radiology Holdings, Inc. (Nasdaq: ... radiology groups across the United States, today announced,that Ernest ... member of the,company,s Board of Directors for personal reasons. ... The company intends to immediately begin a search,to identify ...
... over Prior Year, NEW YORK, Feb. 28 HMS ... quarter and full,year ended December 31, 2007., Revenue for ... with $33.6 million for the same period a year ago. ... common share for the fourth,quarter of 2007, compared to net ...
... 28 VirtualHealth,Technologies, Inc. (OTC Bulletin Board: VHGI) President, ... that predict by 2017, total health,care spending will double ... of every $5 the nation spends according to a ... of the increased costs in health care,projected to top ...
... children with special health care needs, such as autism, ... the care that is federally recommended and that there ... standardized data at the national and state level has ... easily accessible way. , "Parents of children with special ...
... Medical, Inc.,(Nasdaq: ATSI ), manufacturer and marketer ... Dale, President and CEO of,ATS Medical, and Mike ... Renshaw,"Straight to the Heart" conference at the Boston ... the conference is by invitation only. The,conference will ...
... Leonard, Founder and,Chief Surgeon of Leonard Hair Transplant Associates ... availability of a new genetic test for male,pattern baldness. ... England to,offer this to patients., Dr. Robert Leonard ... by genetic male pattern baldness. This exciting new tool ...
Cached Medicine News:Health News:NightHawk Radiology Holdings, Inc. Announces Board Member Departure 2Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 2Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 3Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 4Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 5Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 6Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 7Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 8Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 9Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 10Health News:As Healthcare Spending is Predicted to Exceed 4 Trillion in Less Than 10 Years, Technology will be Called upon to Stem the Tide 2Health News:New child health data show state-to-state differences in quality of care 2Health News:Dr. Robert Leonard First in New England to Offer Genetic Test for Male Pattern Baldness 2
One end with needle point and other end with medium taper. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
This double ended instrument was designed to lift and manipulate the corneal flap in Lasik procedures. Manufactured in titanium....
... This instrument marks the cornea for centration ... flap management in primary and enhancement cases. The ... used to ensure proper alignment of the flap ... atraumatically retract the flap and to flood it ...
Flat curved 1 mm spatula blade 30 mm long with marks at 5 mm, 6 mm and 7 mm from tip, polished finish and round knurled handle. Most popular size or model....
Medicine Products: